Literature DB >> 22399357

Notch inhibition as a promising new approach to cancer therapy.

Benjamin Purow1.   

Abstract

The Notch pathway powerfully influences stem cell maintenance, development and cell fate and is increasingly recognized for the key roles it plays in cancer. Notch promotes cell survival, angiogenesis and treatment resistance in numerous cancers, making it a promising target for cancer therapy. It also crosstalks with other critical oncogenes, providing a means to affect numerous signaling pathways with one intervention. While the gamma-secretase inhibitors are the only form of Notch inhibitors in clinical trials, other forms of Notch inhibition have been developed or are theoretically feasible. In this chapter we review the rationales for Notch inhibition in cancer and then discuss in detail the various modalities for Notch inhibition, both current and speculative.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22399357      PMCID： PMC3361718          DOI： 10.1007/978-1-4614-0899-4_23

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


  111 in total

1.  Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling.

Authors:  Qinghua Zeng; Shenglin Li; Douglas B Chepeha; Thomas J Giordano; Jong Li; Honglai Zhang; Peter J Polverini; Jacques Nor; Jan Kitajewski; Cun-Yu Wang
Journal:  Cancer Cell       Date:  2005-07       Impact factor: 31.743

2.  Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma.

Authors:  Franziska Jundt; Ioannis Anagnostopoulos; Reinhold Förster; Stephan Mathas; Harald Stein; Bernd Dörken
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

3.  NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa.

Authors:  F Oswald; S Liptay; G Adler; R M Schmid
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

4.  Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model.

Authors:  Shigeo Masuda; Keiki Kumano; Takahiro Suzuki; Taisuke Tomita; Takeshi Iwatsubo; Hideaki Natsugari; Arinobu Tojo; Makoto Shibutani; Kunitoshi Mitsumori; Yutaka Hanazono; Seishi Ogawa; Mineo Kurokawa; Shigeru Chiba
Journal:  Cancer Sci       Date:  2009-08-27       Impact factor: 6.716

5.  The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts.

Authors:  Dieter Hartmann; Bart de Strooper; Lutgarde Serneels; Katleen Craessaerts; An Herreman; Wim Annaert; Lieve Umans; Torben Lübke; Anna Lena Illert; Kurt von Figura; Paul Saftig
Journal:  Hum Mol Genet       Date:  2002-10-01       Impact factor: 6.150

6.  Mastermind critically regulates Notch-mediated lymphoid cell fate decisions.

Authors:  Ivan Maillard; Andrew P Weng; Andrea C Carpenter; Carlos G Rodriguez; Hong Sai; Lanwei Xu; David Allman; Jon C Aster; Warren S Pear
Journal:  Blood       Date:  2004-06-08       Impact factor: 22.113

7.  p65-NFkappaB synergizes with Notch to activate transcription by triggering cytoplasmic translocation of the nuclear receptor corepressor N-CoR.

Authors:  Lluís Espinosa; Sara Santos; Julia Inglés-Esteve; Pura Muñoz-Canoves; Anna Bigas
Journal:  J Cell Sci       Date:  2002-03-15       Impact factor: 5.285

8.  Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells.

Authors:  Olivier Meurette; Spyros Stylianou; Rebecca Rock; Giovanna M Collu; Andrew P Gilmore; Keith Brennan
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

9.  Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

Authors:  Leopoldo Luistro; Wei He; Melissa Smith; Kathryn Packman; Maria Vilenchik; Daisy Carvajal; John Roberts; James Cai; Windy Berkofsky-Fessler; Holly Hilton; Michael Linn; Alexander Flohr; Roland Jakob-Røtne; Helmut Jacobsen; Kelli Glenn; David Heimbrook; John F Boylan
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

10.  Notch pathway modulation on bone marrow-derived vascular precursor cells regulates their angiogenic and wound healing potential.

Authors:  Francisco Caiado; Carla Real; Tânia Carvalho; Sérgio Dias
Journal:  PLoS One       Date:  2008-11-18       Impact factor: 3.240
View more
  70 in total

Review 1.  Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.

Authors:  Johan Kreuger; Mia Phillipson
Journal:  Nat Rev Drug Discov       Date:  2015-11-27       Impact factor: 84.694

2.  Obesity Notches up fatty liver.

Authors:  Michael P Czech
Journal:  Nat Med       Date:  2013-08       Impact factor: 53.440

3.  RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer.

Authors:  May Chammaa; Agnes Malysa; Carlos Redondo; Hyejeong Jang; Wei Chen; Gerold Bepler; Rodrigo Fernandez-Valdivia
Journal:  J Cell Physiol       Date:  2018-06-28       Impact factor: 6.384

4.  NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.

Authors:  M P Licciardello; M K Müllner; G Dürnberger; C Kerzendorfer; B Boidol; C Trefzer; S Sdelci; T Berg; T Penz; M Schuster; C Bock; R Kralovics; G Superti-Furga; J Colinge; S M Nijman; S Kubicek
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

5.  The NOTCH4-HEY1 Pathway Induces Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.

Authors:  Takahito Fukusumi; Theresa W Guo; Akihiro Sakai; Mizuo Ando; Shuling Ren; Sunny Haft; Chao Liu; Panomwat Amornphimoltham; J Silvio Gutkind; Joseph A Califano
Journal:  Clin Cancer Res       Date:  2017-11-16       Impact factor: 12.531

Review 6.  Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

Authors:  Tamorah R Lewis; Elaine L Shelton; Sara L Van Driest; Prince J Kannankeril; Jeff Reese
Journal:  Semin Fetal Neonatal Med       Date:  2018-02-24       Impact factor: 3.926

7.  Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.

Authors:  Noémi Nagy; Melinda Hajdu; Ágnes Márk; Péter Attila Király; Mónika Tóth; Titanilla Dankó; Mónika Csóka; Anna Sebestyén
Journal:  Tumour Biol       Date:  2016-07-29

8.  Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies.

Authors:  Meghan A Rice; En-Chi Hsu; Merve Aslan; Ali Ghoochani; Austin Su; Tanya Stoyanova
Journal:  Mol Cancer Ther       Date:  2019-04-26       Impact factor: 6.261

9.  Impaired endolysosomal function disrupts Notch signalling in optic nerve astrocytes.

Authors:  Mallika Valapala; Stacey Hose; Celine Gongora; Lijin Dong; Eric F Wawrousek; J Samuel Zigler; Debasish Sinha
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling.

Authors:  Maria V Guijarro; Sonika Dahiya; Laura S Danielson; Miguel F Segura; Frances M Vales-Lara; Silvia Menendez; Dorota Popiolek; Khushbakhat Mittal; Jian Jun Wei; Jiri Zavadil; Carlos Cordon-Cardo; Pier Paolo Pandolfi; Eva Hernando
Journal:  Am J Pathol       Date:  2013-06       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.